ITC to Assess if Chinese Firm Violated Ventria Bioscience Patents
The International Trade Commission (ITC) has said it will investigate whether Chinese company Wuhan Healthgen Biotechnology is infringing two patents owned by Kansas-based Ventria Bioscience.
Ventria creates genetically programmed rice seeds that express recombinant human proteins known as albumin, which is normally only found in human blood. The albumin is extracted from the rice for use in drugs that include immunotherapy medicines, gene therapies and vaccines.
Ventria alleges that one of its previous employees founded Wuhan Healthgen to make a plant-based albumin using techniques protected by U.S. patents that Ventria holds.